Game-changer for bone mets: PEACE-3 shows enzalutamide + radium-223 improves OS and rPFS vs enzalutamide alone. Expect shifts in first-line care; monitor fracture and HTN risk. Full breakdown → future.xsbrt.com/ProstateCancerRadiumEnza... Save or reply for notes #PEACE3

📢 PEACE‑3 final results: adding radium‑223 to enzalutamide reduces risk of death by 24% in men with #mCRPC and bone metastases.

Results presented at ASCO @ascocancer.bsky.social #GU26 and published in Annals of Oncology.

🔗 Full press release: www.eortc.org/blog/2026/02...

#CancerResearch #PEACE3

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend …

#PEACE3 confirmed efficacy of combo of #Enzalutamide & #Ra223. For any treatment, safety & toxicity equally important. Read our recommendations on use of bone protection @eortc.bsky.social @mcrcnews.bsky.social @ccparker.bsky.social
👇🏽👇🏽👇🏽👇🏽👇🏽👇🏽👇🏽
www.sciencedirect.com/science/arti...